Based on the findings above, to further illustrate the potential association between MAPK7 and efficiency of immunotherapy in melanomas, we constructed an independent validation cohort, containing 27 stage IV melanoma patients with anti-PD1 treatment (18 AMs, 6 CMs, 2 MMs). Here, PDCD1 is linked to melanoma.